In the management of Type-2 diabetes mellitu
LINAGLIPTIN:-
Linagliptin is a dipeptidyl peptidase- 4 (DPP-4) inhibitor.
Linagliptin differs from other DPP-4 inhibitors in that it has a non linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependent protein binding.
METFORMIN(IR):-
Metformin is a biguanide antihyperglycemic agent and firdt line pharmacotherapy used in the management of type 11 diabetes.
Metformin reduces hepatic production of glucose, decreases the intestinal absorption of glucose, and enhances insulin sentivity by increasing both peripheral glucose uptake and utilization